Scott Rocklage is a PhD holder. After joining 5AM Ventures as a venture partner in 2003, he became its Managing Partner in 2004. He attained his B.S., Chemistry from University of California and his PhD., Chemistry from Massachusetts Institute of Technology.
Scott Rocklage has vast knowledge in healthcare management, for over two decades, and has profound leadership skills. Among his accomplishments is being approved application of three drugs; Omniscan, Teslascan, and Cubicin, by the FDA. He has invented over thirty U.S. patents, and he has initiated six drug candidates into clinical trials.
Scott’s strategic leadership has been applied to many companies over the years; He has served as CEO at EPIRUS Biopharmaceuticals, he served as CEO and President of Amersham Health, Dr. Scott served as Executive Chairman and Co-President of Ilypsa, he was a Director at both Achaogen and Pulmatrix. He was as President and CEO of Nycomed Saluter, and was the Chairman and CEO of Cubist Pharmaceuticals, bearing various R&D positions at Saluter and Catalytica. He is recently serving as Chairman of Board at Relypsa and Semprus, and he is a board member at WaveRx, Pulmatrix, and Variation.
5 AM Ventures was founded in 2002, by two partners John Diekman, and Andrew Schwab, and currently, has ninety investments in 47 companies. It deals with Biotechnology, Health Care, Health, and Wellness Companies. 5AM is California based, and it provides seed and early stage investment to its clients.
5AM is dedicated to building new-era science companies and delivering impressive returns to its investors. It works toward diagnosing, preventing, and treating medical related issues. The company has a team of professionals, who are experts in scientific, medical, operational, legal, and finance systems. It is actively involved in helping its clients set up company’s strategy, recruiting management, business development, and fundraising.
5AM employs different strategies to realize its mission;
• Hands-on Approach to company building- takes over short-term roles when starting new enterprises, offering step-by-step guidance throughout the business’s life.
• Team, Network, Extensive Operational Experience-since individuals’ from5AM have spent their lives in the science industry, teamwork is naturally inculcated, and this makes the firm entrepreneur-friendly.
• Capital Efficiency and Shortened Time to Realization- 5AM team maximizes on possible returns generated within three to five years. It sources out non-equity capital and creates early exit opportunities
• Focus on Low Loss Rate- its main agenda is to maximize shareholder returns, redefining business strategy, and restructuring management teams to enhance company performance and overall yields.
Dr. Scott has been a great asset to 5AM Ventures. Having being approved of three U.S. NDA’s and establishing top notch development pipelines, Scott will add significant value to the company. He will contribute to its growth, adding his experience, and expertise. Dr. Scott has worked with many research leadership functions. He will work alongside John, Andy, and Carin Muller in creating and building exclusive biotechnology companies.